Compare · ACCD vs FLAC
ACCD vs FLAC
Side-by-side comparison of Accolade Inc. (ACCD) and Frazier Lifesciences Acquisition Corporation (FLAC): market cap, price performance, sector, and recent activity on the wire.
Summary
- ACCD operates in Consumer Discretionary, while FLAC operates in Finance - the two are in different parts of the market.
- ACCD is the larger of the two at $1.18B, about 6.8x FLAC ($173.8M).
- ACCD has more recent analyst coverage (25 ratings vs 0 for FLAC).
- Company
- Accolade Inc.
- Frazier Lifesciences Acquisition Corporation
- Price
- $7.03+0.00%
- $9.87+4.00%
- Market cap
- $1.18B
- $173.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Business Services
- Business Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2021
- News (4w)
- 0
- 0
- Recent ratings
- 25
- 0
Accolade Inc.
Accolade, Inc. develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was founded in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.
Frazier Lifesciences Acquisition Corporation
Frazier Lifesciences Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses or entities in the biotechnology sector. The company was incorporated in 2020 and is based in Seattle, Washington.
Latest ACCD
- Defining Wellness Centers Names Bill Morrison Chief Financial Officer
- SEC Form 15-12G filed by Accolade Inc.
- Amendment: SEC Form SCHEDULE 13D/A filed by Accolade Inc.
- SEC Form 25-NSE filed by Accolade Inc.
- SEC Form S-8 POS filed by Accolade Inc.
- SEC Form S-8 POS filed by Accolade Inc.
- SEC Form S-8 POS filed by Accolade Inc.
- SEC Form S-8 POS filed by Accolade Inc.
- SEC Form S-8 POS filed by Accolade Inc.
- Chief Executive Officer Singh Rajeev returned $10,429,525 worth of shares to the company (1,483,574 units at $7.03), closing all direct ownership in the company (SEC Form 4)
Latest FLAC
- SEC Form SC 13G/A filed by Frazier Lifesciences Acquisition Corporation (Amendment)
- SEC Form 15-12G filed by Frazier Lifesciences Acquisition Corporation
- SEC Form SC 13G/A filed by Frazier Lifesciences Acquisition Corporation (Amendment)
- SEC Form SC 13D/A filed by Frazier Lifesciences Acquisition Corporation (Amendment)
- SEC Form 4 filed by Viking Global Investors Lp
- Frazier Lifesciences Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 4 filed by Topper David Joseph
- SEC Form 4 filed by Bigham Michael
- SEC Form 4 filed by Polu Krishna R
- SEC Form 4 filed by Baltera Robert Jr.